Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by R. Aljumaily
MA04.02 Responses and Durability in NSCLC Treated With Pegilodecakin and Anti-Pd-1
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
MA04.01 Cemiplimab, a Human Monoclonal Anti-Pd-1, Alone or in Combination With Radiotherapy: Phase 1 NSCLC Expansion Cohorts
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Related publications
Safety and Tumor Responses With Lambrolizumab (Anti–PD-1) in Melanoma
New England Journal of Medicine
Medicine
OA05.01 Efficacy/Safety of Entinostat (ENT) and Pembrolizumab (PEMBRO) in NSCLC Patients Previously Treated With Anti-Pd-(L)1 Therapy
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P1.01-08 Hyperresponsive Disease: A New Pattern of Response in NSCLC Patients Treated by Anti-Pd-1/Pd-L1
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Can IDO Activity Predict Primary Resistance to Anti-Pd-1 Treatment in NSCLC?
Journal of Translational Medicine
Biochemistry
Medicine
Genetics
Molecular Biology
Comprehensive Molecular and Clinical Characterization of Asian Melanoma Patients Treated With Anti-Pd-1 Antibody
BMC Cancer
Cancer Research
Oncology
Genetics
MA11.06 Prognostic Value of Complement System in NSCLC and Its Association With PD-1 and PD-L1 Expression
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
022 Diet-Induced Obesity Predisposes Anti-Pd-1 Antibody-Treated Mice to Imiquimod-Mediated Psoriasiform Dermatitis: Implications for Immune-Related Adverse Events in Cancer Patients Treated With Anti-Pd-1
Journal of Investigative Dermatology
Biochemistry
Dermatology
Cell Biology
Molecular Biology
SCLE and Dermatomyositis in Anti‐PD‐1 Therapy
British Journal of Dermatology
Dermatology
Medicine
